[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617174":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":19,"interventions":30,"overallOfficials":11,"centralContacts":40,"locations":49,"responsibleParty":69,"collaborators":11,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":11,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":11,"overallStatus":52,"whyStopped":11,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Capital Institute of Pediatrics, China","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Percentage of Subjects with a Reduction in 24-Hour Urinary Protein Excretion ≥30% from Baseline",null,"3 months",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":11},"NONE",[20,25],{"label":21,"type":22,"description":11,"interventionNames":23},"Finerenone group","EXPERIMENTAL",[24],"Drug: ACEI \u002F ARB+finerenone",{"label":26,"type":27,"description":11,"interventionNames":28},"Control group","ACTIVE_COMPARATOR",[29],"Drug: ACEI\u002FARB",[31,36],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":11},"DRUG","ACEI \u002F ARB+finerenone","In the finerenone group, finerenone was administered orally on the basis of combined oral ACEI\u002FARB, with the dose calculated based on body surface area, once a day for 3 months.",[21],{"type":32,"name":37,"description":38,"armGroupLabels":39,"otherNames":11},"ACEI\u002FARB","The control group was only given oral ACEI\u002FARB for 3 months.",[26],[41,46],{"name":42,"role":43,"phone":44,"phoneExt":11,"email":45},"Yue Jia","CONTACT","86+13681366590","kamui1127@126.com",{"name":47,"role":43,"phone":48,"phoneExt":11,"email":11},"Juan Tu","86+13021049832",[50],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Capital Center for Children's Health,Capital Medical University","RECRUITING","Beijing","Beijing Municipality","100020","China","CN",{"type":59,"coordinates":60},"Point",[61,62],116.39723,39.9075,{"lat":62,"lon":61},[65],{"name":66,"role":43,"phone":67,"phoneExt":11,"email":68},"Haiyun Geng","86+13681078655","hygjing@126.com",{"type":70,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100617174","phase-4-finerenone-therapy-for-pediatric-hspn-with-mild-proteinuria-100617174",false,"NCT07315191","Finerenone Therapy for Pediatric HSPN With Mild Proteinuria","The Randomized Controlled Trial of Finerenone Therapy for Pediatric Hennoch Scholein Nephritis With Mild Proteinuria","FICHSPN","Inclusion Criteria:\n\n1. Children of HSPN meet the following conditions① Age \\> 3 years old and \\\u003C 18 years old;\n2. 24-hour urine protein quantification \\>= 8mg\u002Fh\u002FM2 body surface area (or \\>= 300mg\u002Fd), and \\\u003C 20mg\u002Fh\u002FM2 body surface area (\\\u003C 1000mg\u002Fd);\n\n3: 3. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. Abnormal renal function: eGFR \\\u003C 90 ml\u002Fmin\u002F1.73m\\^2 body surface area;\n2. Renal pathological grade \\>= IV;\n3. Application of glucocorticoids and\u002For immunosuppressants within 2 weeks;\n4. Recent applications involving high-dose glucocorticoids administered for a duration exceeding two weeks.;\n5. Liver transaminase \\> 2 times the upper limit of normal;\n6. Severe cardiac insufficiency;\n7. Simultaneous use of CYPA4 inhibitors;-","ALL","3 Years","18 Years",{"count":83,"type":84},116,"ESTIMATED","INTERVENTIONAL",[87],"PHASE4","Henoch-Schönlein purpura nephritis (HSPN) is the most common secondary glomerular disease in children. About 40% of HSPN cases are accompanied by mild proteinuria, and some of them progress to end-stage renal disease. Currently, the treatment for children with mild proteinuria HSPN mainly involves ACEI\u002FARB, but long-term use of these drugs can lead to an increase in aldosterone levels, affecting therapeutic efficacy. Finerenone can improve vascular endothelial cell dysfunction and renal tissue inflammation and fibrosis, and reduce urinary protein in patients with glomerular diseases. This study intends to conduct an exploratory randomized controlled clinical trial of finerenone in children with HSPN accompanied by a small amount of proteinuria to evaluate the efficacy and safety of finerenone treatment.",[90],"Henoch Schönlein Purpura Nephritis","2026-01-05",{"date":93,"type":94},"2026-01-07","ACTUAL",{"date":96,"type":94},"2025-06-13",{"date":98,"type":84},"2028-04-30",{"name":5,"class":6},1]